• Molecular NameTrihexyphenidyl
  • SynonymTrihexifenidilo [INN-Spanish]; Trihexylphenidyl; Trihexylphenidyle; Trihexylphenizyl; Trihexyphenidyl HCl; Trihexyphenidyle; Trihexyphenidyle [INN-French]; Trihexyphenidylum [INN-Latin]; Triphenidyl
  • Weight301.474
  • Drugbank_IDDB00376
  • ACS_NO144-11-6
  • Show 2D model
  • LogP (experiment)4.49
  • LogP (predicted, AB/LogP v2.0)4.64
  • pkaN/A
  • LogD (pH=7, predicted)2.26
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.17
  • LogSw (predicted, AB/LogsW2.0)0.24
  • Sw (mg/ml) (predicted, ACD/Labs)0.14
  • No.of HBond Donors1
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds5
  • TPSA23.47
  • StatusFDA approved
  • AdministrationOral, as tablet or elixir
  • PharmacologyAn antiparkinsonian drug of the antimuscarinic class -- specifically at equivalent doses it has 83 per cent of the antimuscarinic power of atropine.
  • Absorption_value100.0
  • Absorption (description)Trihexyphenidyl is rapidly absorbed from the gastrointestinal tract.
  • Caco_2N/A
  • Bioavailability100.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half life3.3~4.1 h
  • ExcretionIt is excreted in the urine, probably as unchanged drug.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include mydriasis, dryness of mucous membranes, red face, atonic states of bowels and bladder, and hyperthermia in high doses. Central consequences are agitation, confusion, and hallucinations. An untreated overdose may be fatal, particular in children. Premortal signs are respiratory depression and cardiac arrest.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A